Active, Not Recruiting
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
NCT05501054
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- Duke Cancer Institute Durham, North Carolina, United States
- Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States
- M D Anderson Cancer Center Houston, Texas, United States